Galantamine (Amaryllidaceae Alkaloid · AChE Inhibitor · Alzheimer's FDA-approved · Informational)
| Compound | Galantamine (Galanthamine) |
| Chemical class | Alkaloid — Amaryllidaceae (Benzazepine; tertiary alkaloid with phenanthrene-type scaffold) |
| CAS | 357-70-0 |
| Primary source | Galanthus nivalis (common snowdrop), Galanthus woronowii (Woronow’s snowdrop), Narcissus spp. |
| Key applications | Pharmaceutical AChE inhibitor for Alzheimer's disease (FDA-approved); nicotinic receptor allosteric sensitiser; informational reference |
| Claim strength | High (as pharmaceutical for Alzheimer's); Informational only |
| Typical form | Pharmaceutical tablet/oral solution (Razadyne/Reminyl); not a dietary supplement in regulated markets |
| Buy from Herbuno | Browse HerbIQ Compound Index → |
Name origin: From Galanthus (snowdrop genus). Galantamine was first isolated from Galanthus woronowii (Woronow’s snowdrop) by Soviet chemists in the 1950s, and independently from G. nivalis (common snowdrop) by Bulgarian chemist Dimitar Paskov in 1956. The drug was used clinically in Eastern Europe and China before its development as an Alzheimer’s treatment in the 1990s. Mechanism — dual cholinergic action: Galantamine is a reversible, competitive AChE inhibitor (increasing synaptic ACh) — the same class as donepezil and rivastigmine. Uniquely, galantamine is also an allosteric sensitiser of nicotinic ACh receptors (nAChRs): it potentiates ACh-mediated nAChR activation, enhancing cholinergic neurotransmission beyond simply blocking ACh breakdown. This dual mechanism distinguishes galantamine from other approved AChE inhibitors. FDA approval and clinical use: Galantamine (Razadyne, formerly Reminyl) is FDA-approved for mild-to-moderate Alzheimer’s dementia. In head-to-head comparisons, galantamine, donepezil, and rivastigmine show similar efficacy — the choice between them is based on tolerability, dosing convenience, and individual patient factors. Traditional use context: Soviet-era use of galantamine (Nivalin) predates the modern Alzheimer’s indication — it was used for post-poliomyelitis and peripheral nerve injury rehabilitation due to its nicotinic-stimulating properties. This is the traditional basis for its neurological applications. Supplement status: FDA-approved pharmaceutical; not a dietary supplement. Marketing galantamine as a supplement for Alzheimer’s or memory enhancement is not permitted in regulated markets.
Galantamine — Pharmaceutical Context
AChE inhibition for Alzheimer’s disease: Galantamine at 16–24 mg/day (extended-release) produces statistically significant improvements on cognitive assessment scales (ADAS-cog, MMSE) compared to placebo in mild-to-moderate AD patients. Effect sizes are modest (2–4 ADAS-cog points) reflecting symptomatic benefit without disease modification. Galantamine does not slow the underlying neurodegenerative process. Its nAChR allosteric sensitisation may provide additional benefit beyond simple AChE inhibition in some patients. Pharmaceutical evidence: High.
Nicotinic receptor allosteric sensitisation: Galantamine binds to an allosteric site on nAChR (distinct from ACh binding site), increasing the probability of channel opening in response to ACh. This mechanism — unique among approved AChE inhibitors — may contribute to galantamine’s neuroprotective effects beyond symptomatic cholinergic enhancement. The α7-nAChR subtype is particularly relevant for cognitive function and neuroinflammation modulation. Pharmacological reference; clinical significance of dual mechanism vs AChE inhibition alone is debated.
Snowdrop extraction vs total synthesis: Commercial galantamine was initially sourced by extraction from Galanthus bulbs — but snowdrop bulb yield is low and extraction is labour-intensive. Several total synthesis routes have been developed (the Trost synthesis, 2005, being the most elegant). Commercial production now primarily uses either synthetic routes or semi-synthetic methods from lycoris alkaloid precursors available from Narcissus species. Commercial chemistry reference.
This compound is documented for research and formulator education purposes. For commercially available botanical ingredients, explore the HerbIQ Compound Index →
Frequently Asked Questions — Galantamine
Is galantamine better than donepezil for Alzheimer’s?
Head-to-head trials show no clinically meaningful difference in cognitive outcomes between galantamine, donepezil, and rivastigmine. Choice is based on tolerability (donepezil once-daily convenient; galantamine twice-daily standard, once-daily extended-release; rivastigmine patch for GI-sensitive patients), cost (donepezil is most widely generic), and specific patient factors. The dual mechanism of galantamine (AChE inhibition + nAChR sensitisation) is mechanistically appealing but has not translated to measurable clinical superiority in controlled trials.
Why can’t galantamine be sold as a brain supplement?
Galantamine was approved as a pharmaceutical drug (Reminyl/Razadyne) before any supplement marketing. FDA’s drug preclusion rule (same as nicotine) means that once a compound has been investigated as a drug, it cannot be marketed as a dietary supplement. Additionally, galantamine’s clinical use requires medical monitoring for dose titration and GI side effect management — OTC supplement marketing would be inappropriate for a compound requiring this clinical oversight.
Is the snowdrop (Galanthus) toxic?
Yes — Galanthus bulbs contain galantamine and related Amaryllidaceae alkaloids (lycorine, narciclasine) that are toxic if ingested in significant quantities. Galantamine itself at pharmaceutical doses causes nausea, vomiting, diarrhoea, and bradycardia via cholinergic excess — these are dose-limiting side effects requiring careful titration. Snowdrop bulbs can be confused with wild garlic or wild onion bulbs, causing poisoning incidents. All parts of Galanthus are considered poisonous for ingestion without pharmaceutical extraction and purification.
What is the traditional Soviet use of galantamine?
Galantamine (as Nivalin) was used in Soviet-era medicine for post-poliomyelitis syndrome, myasthenia gravis, and peripheral nerve injury — exploiting its nicotinic receptor-stimulating properties to improve neuromuscular transmission in damaged or weakened neuromuscular junctions. This traditional Eastern European application predates the Alzheimer’s indication by decades and demonstrates that galantamine’s neurological applications were recognised before modern cholinergic AD hypothesis research.
Related compounds: Huperzine-A, Pilocarpine, Morphine, Nicotine
Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.
← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery